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Abstract
Background: Our group has developed a new process for isolating and identifying novel cationic antimicrobial
peptides from small amounts of biological samples. Previously, we identified several active antimicrobial peptides
from 100 μl of plasma from Alligator mississippiensis. These peptides were found to have in vitro antimicrobial
activity against Pseudomonas aeruginosa and Staphylococcus aureus. In this work, we further characterize three of
the novel peptides discovered using this process: Apo5, Apo6, and A1P.
Results: We examined the activity of these peptides against multi-drug resistant strains and clinical isolates of
common human pathogens. We investigated their structural characteristics using circular dichroism and tested for
membrane disruption and DNA binding. These peptides were found to have strong in vitro activity against multi-drug
resistant and clinically isolated strains of S. aureus, Escherichia coli, P. aeruginosa, and Acinetobacter baumannii. Apo5 and
Apo6, peptides derived from alligator apolipoprotein C-1, depolarized the bacterial membrane. A1P, a peptide from the
serpin proteinase inhibitor, did not permeabilize membranes. Performing circular dichroism analysis, Apo5 and Apo6
were found to be predominantly helical in SDS and TFE buffer, while A1P has significantly different structures in
phosphate buffer, SDS, and TFE. None of these peptides were found to be hemolytic to sheep red blood cells or
significantly cytotoxic up to 100 μg/ml after 24 h exposure.
Conclusions: Overall, we suggest that Apo5 and Apo6 have a different mode of action than A1P, and that all three
peptides make promising candidates for the treatment of drug-resistant bacteria, such as A. baumannii.
Keywords: Antimicrobial peptides, Alligator mississippiensis, Multi-drug resistant bacteria, Acinetobacter baumannii,
Escherichia coli, Staphylococcus aureus
Background
Cationic antimicrobial peptides (CAMPs) are short pro-
teins produced by the innate immune system of virtually
all eukaryotic organisms [1]. CAMPs have a variety of
structures, such as helical, beta-sheet, or mixed struc-
tures [2], and antibacterial mechanisms, including mem-
brane perturbation [3], DNA binding [4], and enzyme
interference [5]. There has been strong interest in the
discovery and exploration of CAMPs due to rising drug
resistance in pathogenic bacteria and the subsequent
need for new therapeutics [1]. Traditionally, new
CAMPs are identified through either bioinformatics or
fractionation. CAMPS are a diverse group of peptides
that can differ by nucleic acid sequence, amino acid se-
quence, and secondary structure [2], which can compli-
cate the process of locating new CAMPs by analysis of
gene and protein databases. Fractionation through HPLC
or other methods typically requires large amounts of
biological sample, usually a liter or more [6], which can be
problematic when working with small or endangered ani-
mals. Fractionation and testing can also be challenging
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due to dilution of samples, as CAMPs can be present in
very small amounts [6, 7].
Our group recently developed a novel and powerful
process for discovering and identifying new and poten-
tially useful CAMPs from biological samples, called the
Bioprospecter process [8]. Our CAMP discovery process
is sample-agnostic and requires very small sample vol-
umes for analysis. We have successfully employed this
process to discover a large number of new peptides from
100 μl of plasma from the American alligator, Alligator
mississippiensis; five of these show antibacterial activity
against Gram-positive and/or Gram-negative bacteria.
Moreover, it is unique in its approach to CAMP identifi-
cation in that it directly mines the native antimicrobial
peptidome through custom-made hydrogel particles
whose properties complement the physico-chemical
properties of CAMPs [8]. This bioprospecting approach
provides us access to the CAMP peptidomes of some of
the world’s most remarkable species, to dramatically ex-
pand the current CAMP library and potentially unlock
the key to overcoming antibiotic resistance via the dis-
covery of new antimicrobial peptides.
Using this tool, we previously described three novel
peptides from A. mississippiensis (Apo5, Apo6, and A1P)
with activity against laboratory strains of E. coli, P. aeru-
ginosa, S. aureus, and Bacillus cereus [8]. Apo5 and
Apo6 are highly related peptides; nested fragments of a
purported apolipoprotein. Apolipoproteins have anti-
microbial activity against a variety of pathogenic bacteria
[9–14] (see Discussion). A1P is the C-terminal fragment
of alpha-1-proteinase inhibitor of the serpin family; this
protease inhibitor has broad protease inhibiting activity,
as well as immunomodulatory effects [15]. In this work,
we further characterize the antimicrobial activity of these
peptides against bacterial pathogens resistant to multiple
antibiotics as well as clinical isolates, including multi-
drug resistant A. baumannii, which was not previously
tested. In addition, we sought to determine the second-
ary structure of these peptides in order to understand




Staphylococcus aureus ATCC 33592 (MDR) and BAA-
1718, Escherichia coli ATCC 51659 (MDR) and 4157,
Pseudomonas aeruginosa ATCC BAA-2110 (MDR), and
Acinetobacter baumannii ATCC BAA-1794 (MDR) and
9955 were purchased from the American Type Culture
Collection (Manassas, VA). Pseudomonas aeruginosa
strain PAO1 was generously provided by Karin Sauer
from Binghamton University (Binghamton, NY). All
strains are clinical isolates except for E. coli ATCC 4157.
Bacteria were grown in Nutrient Broth (Difco 234000)
overnight in a shaking incubator (37 °C). Bacteria were
aliquoted and frozen at -80 °C and enumerated via serial
dilution and plating prior to experimentation.
Peptides
All peptides were synthesized to order by ChinaPeptides,
Inc (Shanghai, China) using Fmoc chemistry. Peptides
were provided at >95 % purity, and purity and structure
were confirmed with RP-HPLC and ESI-MS.
Bioinformatics
Physiochemical properties were calculated using the
Antimicrobial Peptide Database (APD2) [16]. The per-
cent hydrophobicity is defined as the ratio of hydropho-
bic residues to total residues. The full-length sequences
for the apolipoprotein C-1 containing Apo5 and Apo6
(Accession XP_006276575.1) and for the alpha-1-
proteinase containing A1P (Accession XP_006266331.1)
were found on the BLAST NCBI database [17]. Ribbon
models displaying the full proteins were created using
SWISS MODEL [18–20]. The A. mississippiensis apolipo-
protein C-1 was modeled on the human apolipoprotein
C-1 (SMTL id: 1ioj.1.A, Sequence identity = 43.40 %),
and the A. mississippiensis alpha-1-proteinase was
modeled on alpha1-antitrypsin (SMTL id: 3dru.1.A,
Sequence identity = 51.41 %) [18–23]. The secondary
structure of Apo5, Apo6, and A1P was predicted using I-
TASSER [24] and visualized with Chimera [25]. Helical
wheel projections and hydrophobic moment were calcu-
lated using HeliQuest [26].
Circular dichroism spectroscopy
Circular dichroism (CD) was performed using a Jasco J-
1500 spectropolarimeter. 100 μg/ml of peptide was used
in each experiment. Samples were allowed to equilibrate
for 3 min prior to data collection at 25 °C in a 1 mm
path length cuvette. Spectra were collected from 190 to
260 nm at 0.2-nm intervals, with a data integration time
of 4 s and a 1 nm bandwidth. Data presented is an aver-
age of four spectra. Peptides were analyzed in 10 mM
sodium phosphate buffer (6.12 mM sodium monohydro-
gen phosphate heptahydrate; 3.92 mM monosodium
phosphate anhydrous; pH 7.4), 50 % (v/v) trifluoroethanol
(TFE) in phosphate buffer, or 60 mM sodium dodecyl sul-
fate (SDS) in phosphate buffer. Percent contribution to
secondary structure was measured using methods deter-
mined by Raussens et al. [27].
Antimicrobial assays
The antimicrobial MIC activity of the peptides was
first determined in cation-adjusted Mueller Hinton
Broth (BD 212322) in a 96 well plate following the
CLSI protocol. Enumerated bacteria were diluted in
broth and 105 CFU was added to each well with
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varying dilutions of peptide. The plate was incubated
for 24 h at 37 °C and then read on a spectrophotom-
eter at OD600 nm.
The EC50 antibacterial activity of the peptides was de-
termined in 10 mM phosphate buffer using resazurin as
an indicator of CFU as previously described and vali-
dated by Bishop et al. [8] or by colony counting. The se-
quences and net charges of the peptides tested are
shown in Table 1. In a polypropylene 96 well plate, 105
bacteria were incubated in 10 mM phosphate buffer with
various dilutions of peptide (3 h; 37 °C) (1:5). For the
resazurin method, cation-adjusted Mueller Hinton Broth
(BD 212322, final concentration 2.2 %) and resazurin
(final concentration 109 μM) dissolved in PBS were
added to each well, and the plate was read kinetically
overnight on a Tecan Safire2 spectrofluorometer (37 °C;
excitation = 540 nm; emission = 590 nm). Percent sur-
vival after treatment was then calculated with previously
determined growth curves (Table 2). For colony counting,
experimental wells were serially diluted after incubation,
and 8 μl of each dilution was spotted onto cation-adjusted
Mueller Hinton Agar (BD 211438) and allowed to dry.
Agar plates were then incubated overnight at 37 °C. After
incubation, colonies were counted and percent survival
was calculated based on untreated bacteria. GraphPad
Prism 6.0 was used to calculate EC50 using log concentra-
tion vs. percent survival. LL-37, polymyxin B (against
Gram-negative bacteria), and vancomycin (against Gram-
positive bacteria) are used as controls. LL-37 is a well-
studied human CAMP with broad-spectrum antimicrobial
activity, polymyxin B is a peptide antibiotic effective
against Gram-negative bacteria, and vancomycin is a
peptide antibiotic used against Gram-positive bacteria.
Each experiment was repeated at least twice, and a repre-
sentative experiment is shown. 95 % confidence intervals
(CI) are reported to indicate the error of each EC50
determination.
Ethidium bromide uptake assay
The ethidium bromide uptake assay was performed as
previously detailed [28, 29] with some modifications. E.
coli ATCC 51659 was grown overnight in cation-
adjusted Mueller Hinton Broth in a shaking incubator
(37 °C). Bacteria was centrifuged, washed with PBS, and
then adjusted to an OD600 nm of 0.1 in 10 mM
phosphate buffer. 180 μl of bacteria was added to 10 μl
ethidium bromide (10 mM final concentration) and
10 μl peptide in various concentrations. The plate was
read in a Tecan Safire2 spectrofluorometer every 2 min
for 30 min (37 °C; excitation = 540 nm; emission =
590 nm). Peak RFU at 50 μg/ml was used in Fig. 5.
Membrane depolarization study
Membrane depolarization was studied using DiSC3(5) as
has previously been reported [30]. Depolarization of a
membrane can be visualized by a drop in fluorescence.
Enumerated frozen bacteria were pelleted and washed
twice in 10 mM phosphate buffer and then resuspended
to 4x107 CFU/ml in 10 mM phosphate buffer containing
50 μg/ml DiSC3(5). 100 μl of this suspension was added
to wells of a black 96 well plate. The plate was incubated
in a Tecan Safire2 spectrofluorometer and monitored
until fluorescence leveled off. 100 μl of various concen-
trations of peptide in 10 mM phosphate buffer was
added to each well. Bacteria without peptide and peptide
without bacteria served as controls. The plate was im-
mediately returned to the spectrofluorometer. Readings
were taken every 15 s for 5 min (excitation = 622 nm;
emission = 670 nm). Peak RFU at each concentration
was used in Fig. 6.
Gel shift assay
Non-specific DNA-peptide binding was determined by a
gel-retardation experiment as described by Park et al.
[4]. Briefly, 200 ng of plasmid DNA (pTrcHis, Invitrogen
V36020) was incubated with increasing concentrations
of peptides in 20 μl of binding buffer (5 % glycerol,
10 mM Tris–HCl [pH 8.0], 1 mM EDTA, 1 mM DTT,
20 mM KCl and 50 μg/ml BSA) at room temperature for
20 min and subjected to electrophoresis on a 1.0 %
agarose gel. DNA bands were visualized by ethidium
bromide staining.
Hemolysis and MTT assays
To measure the hemolytic activity of peptides, 2 % sheep
red blood cells were added to various dilutions of pep-
tide reconstituted in PBS in a sterile U-bottom 96 well
plate. 2 % RBCs with PBS 1X alone served as the nega-
tive control, and 2 % RBC in water as the positive con-
trol. The plate was incubated for 1 h at 37 °C and then
Table 1 Amino acid sequences and molecular weights of selected peptides (identified in [8])
Peptide name Sequence Molecular weight Charge Hydrophobicity Length
Apo5 APOC164-88 FSTKTRNWFSEHFKKVKEKLKDTFA 3103.57 +4 32 % 25
Apo6 APOC167-88 KTRNWFSEHFKKVKEKLKDTFA 2766.49 +4 31 % 22
A1P394-428 PPPVIKFNRPFLMWIVERDTRSILFMGKIVNPKAP 4106.28 +4 45 % 35
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 4493.33 +6 35 % 37
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centrifuged at 1000 rpm for 2 min. The supernatant was
transferred to a fresh plate and read at OD540 [31].
Cytotoxicity assays were performed using the Vybrant
MTT Cell Proliferation Assay Kit (Life Technologies) ac-
cording to manufacturer’s instructions. Assays were per-
formed using human lung epithelial lung carcinoma line
A549 (ATCC CCL-185), which were maintained at a low
passage in Dulbecco’s Minimal Essential Media (Life
Technologies 11995073) with 10 % heat-inactivated fetal
bovine serum and 13 U/ml penicillin-streptomycin. 1–
100 μg/ml of peptide was used for each experimental
well. Each experiment was performed in triplicate two
times. A representative experiment is shown.
Statistics
Statistical analyses were performed using GraphPad
Prism 6.0. To determine statistical significance, the one-
way ANOVA with Tukey’s multiple comparisons was
performed in all instances.
Results
Bioinformatics
The native, plasma-derived peptide sequences from the
de novo sequencing [8] were used to predict the second-
ary structure and placement within the parent proteins.
Apo5 and Apo6 are both part of the C-terminus of an
apolipoprotein, apolipoprotein C-1. Apo5 comprises
amino acids (aa) 64-86, while Apo6 is the smaller frag-
ment (aa 67-86, shown in Fig. 1a). Both peptides have a
+4 charge and a hydrophobic ratio of just over 30 % as
determined using APD2 [16]. Apo5 is cleaved at a Glu-
Phe site and Apo6 at a Thr-Lys site. In the full apolipo-
protein, both cleavages sites are located in a disordered
hinge preceding a C-terminal alpha helix as seen in
Fig. 1c.
A1P is also the cleaved C-terminus of its parent pro-
tein, a serpin proteinase inhibitor (aa 394-428, shown in
Fig. 1b). It carries a +4 charge and a 45 % hydrophobi-
city ratio. The peptide is cleaved from the parent protein
at Asp-Pro site in a disordered region on the exterior of
the folded protein, as shown in Fig. 1d. The cleaved pep-
tide itself consists of the two β-sheet regions that run
through the interior of the proteinase.
Secondary structure determination
To determine general secondary structure of Apo5,
Apo6, and A1P, CD spectroscopy was used. CD was per-
formed in 10 mM phosphate buffer, 60 mM SDS, and
50 % TFE in phosphate buffer. Many CAMPs, such as
Table 2 Antimicrobial assay bacterial reduction rate equations
used to determine CFU after incubation with peptide
Bacterial strain Reduction rate equation
P. aeruginosa PAO1 log(CFUP.aeruginosa) = (T20000 – 60948) / -5823.3
E. coli ATCC 51659 log(CFUE. coli) = (T20000 – 37673) / -4292.9
S. aureus ATCC 33592 log(CFUS. aureus) = (T20000 – 59514) / -7912.2
A. baumannii
ATCC BAA-1794
log(CFUA. baumannii) = (T20000 – 34042) / -4398.1
Fig. 1 Primary and tertiary structure of parental proteins and peptide placement within. a Amino acid sequence of A. mississippiensis
apolipoprotein C-1 and the Apo5 and Apo6 fragments. b Amino acid sequence of A. mississippiensis alpha-1-proteinase 2-like protein and the A1P
fragment. c Ribbon model of apolipoprotein C-1 showing cleavages points of Apo5 (long dashes) and Apo6 (short dashes). d Ribbon model of
alpha-1-proteinase showing cleavage point of A1P
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LL-37, maintain a random or disordered structure until
associated with a membrane or micelle. SDS forms mi-
celles with a negatively charged surface [32], mimicking
the bacterial membrane and forcing the CAMP into a
more ordered conformation [33, 34].
TFE is used in CD to promote a helical structure
[35] and stabilize secondary structure [36].
As expected, Apo5 (Fig. 2a) and Apo6 (Fig. 2b) had
nearly identical CD spectra. Both peptides have random
coil and β-sheet characteristics in 10 mM phosphate
buffer, and are primarily α-helical when CD is measured
in buffers with SDS and TFE. Interestingly, Apo5, the
longer of the two peptides, is calculated to have more α-
helical character than Apo6 in both SDS (63.3 % vs.
57.0 %) and TFE (51.0 % vs. 50.3 %), shown in Table 3.
When evaluating the α-helical properties of these two
peptides by simple intensity at 208 nm and 222 nm, it is
notable that the peaks at these wavelengths are more in-
tense for Apo5 than Apo6, though the two Apo peptides
maintain 12.5 % turn no matter the buffer used. Apo5
and Apo6 likely have a primarily α-helical structure with
some random coil portions. Based on helical wheel pro-
jections, it appears that both Apo5 and Apo6 have sig-
nificant amphipathic character, with several hydrophobic
residues on one face and several basic amino acids on
the other. The structure of Apo5 and Apo6 were pre-
dicted using I-TASSER and the resulting.pdb file was vi-
sualized using Chimera, shown in Fig. 3a and b.
Consistent with the CD spectra, both are predicted to be
α-helical structures. Apo5, the longer peptide, has a lon-
ger random coil portion at the N-terminus. This is consist-
ent with the predicted structure of the C-terminal portion
of the parental protein, apolipoprotein C-1 (Fig. 1c). Be-
cause Apo5 and Apo6 are predicted to helical, helical
wheels were produced using Heliquest and modified (Fig. 4).
Apo5 and Apo6 have a similar hydrophobic moment (0.436
vs 0.484); Apo6 likely has a slightly stronger hydrophobic
moment due to the loss of polar Ser in the hydrophobic
face of the helix. In 10 mM phosphate buffer, TFE, and
SDS, A1P has significantly different spectra (Fig. 2c).
In 10 mM phosphate buffer, A1P is calculated to have
primarily β-sheet contributions (57.9 %), as well as some
random coil characteristics (34.7 %), shown in Table 3.
By our calculations, A1P also has a negative percent-
age of contribution from the α-helix, which may be
Fig. 2 CD spectra of peptides to determine secondary structure.
a Apo5, b Apo6, c A1P. All spectra were taken with peptide
concentrations of 100 μg/ml in a 1 mm pathway cuvette. Spectra
were read in 10 mM phosphate buffer (long dashes), 50 % TFE in
10 mM phosphate buffer (dash dot dash), and 60 mM SDS in 10 mM
phosphate buffer (solid line)
Table 3 Percent secondary structure contribution as calculated
by a method described by Raussens et al. [27]
α-helical β-sheet Turn Random Sum
Apo5
Phosphate Buffer 8.9 30.3 12.5 40.6 92.3
TFE 51 4.6 12.5 29.3 97.4
SDS 63.3 -4.8 12.5 25.1 96.1
Apo6
Phosphate Buffer 9.4 30.5 12.5 41 93.4
TFE 50.3 4.8 12.5 29.7 97.3
SDS 57 0.7 12.5 26.9 97.1
A1P
Phosphate Buffer -14.4 57.9 12.4 34.7 90.6
TFE 38.2 16.3 12.5 31.2 98.2
SDS 21.6 24.2 21.5 36.9 104.2
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an artifact of the equations used. In TFE, A1P main-
tains its random coil nature (31.2 %), but also be-
comes strongly α-helical (38.2 %), with only 16.3 %
contribution from the β-sheet. In SDS, A1P is calcu-
lated to be nearly equal parts random coil (36.9 %), turn
(21.5 %), β-sheet (24.2 %), and α-helix (21.6 %). It has been
shown by several groups that TFE can induce and support
α-helical structures in peptides [37, 38]. By qualitatively
evaluating the spectra, we conclude that only in TFE does
A1P have a notable α-helical structure, though this con-
formation may be interrupted by several proline residues
found along the polypeptide chain. It is likely that A1P
has a mixed structure that may change dramatically based
on environmental factors. The secondary structure of A1P
was predicted by I-TASSER and visualized using Chimera.
I-TASSER predicts that A1P is primarily random coil with
two anti-parallel β-sheet in a hairpin formation (Fig. 3c),
which corresponds with the structure of the full alpha-1-
proteinase structure.
Antimicrobial activity
Previously, we reported that Apo5 and Apo6 had strong
broad-spectrum antimicrobial activity against E. coli and
B. cereus, as well as S. aureus and P. aeruginosa [8]. It
was also found that A1P had greater activity against S.
aureus than P. aeruginosa [8], indicating it may have
stronger activity against Gram-positive organisms.
Antibiotic resistance has been increasing steadily for
the past several decades, and CAMPs are considered a
possible basis for novel antimicrobials. Because of this,
these new peptides were tested against clinically isolated
and multi-drug resistant strains of S. aureus, E. coli, P.
aeruginosa and A. baumannii. Numerical and statistical
data can be found in Table 4. Sharing a salt-sensitive
phenotype with LL-37 [34, 39, 40], these peptides had
no effect in MIC experiments as high as 250 μg/ml, so
experiments were performed to determine the EC50 in
10 mM phosphate buffer. We performed these low-salt
experiments using vancomycin as a control for Gram-
positive bacteria and polymyxin B as a control for
Gram-negative bacteria. Polymyxin B was found to be
very effective against all strains tested, with all EC50
values being under 1 μg/ml, except against E. coli ATCC
4157 (2.50 μg/ml). In the case of vancomycin, we found
that this antibiotic did not kill either S. aureus strain
under 100 μg/ml, though the MIC for both strains was
1 μg/ml, indicating that vancomycin is bacteriostatic but
not reliably bactericidal.
Fig. 3 Secondary structure prediction by I-TASSER [24], visualized by Chimera [25]. a Apo5, b Apo6, c A1P
Fig. 4 Helical wheels of a Apo5 and b Apo6, modified from Heliquest
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In general, it was found that the EC50 values of Apo5
and Apo6 were statistically similar and showed broad-
spectrum activity. We found that both apolipoprotein-
derived peptides had strong activity against a clinical iso-
late of S. aureus ATCC BAA-1718 (EC50 < 5 μg/ml).
Both Apo5 and Apo6 were found to have very strong
Table 4 Antimicrobial activity and statistical data
Peptide Bacteria MIC (μg/ml) EC50 (μg/ml) 95 % CI (μg/ml) EC50 (μM)
Apo5 E. coli ATCC 4157 NT 19.7 13.1 to 29.6 6.35
E. coli ATCC 51659 >250 13.9 10.7 to 18.0 4.48
S. aureus ATCC BAA-1718 NT 4.96 2.82 to 8.72 1.60
S. aureus ATCC 33592 >250 0.0680 0.124 to 0.357 0.0219
P. aeruginosa PAO1 >250 0.0878 0.0326 to 0.237 0.0283
P. aeruginosa ATCC BAA-2110 NT 0.467 0.234 to 0.934 0.150
A. baumannii ATCC 9955 NT 0.644 0.480 to 0.865 0.207
A. baumannii ATCC BAA-1794 >250 0.234 0.122 to 0.450 0.0755
Apo6 E. coli ATCC 4157 NT 3.85 2.71 to 5.48 1.39
E. coli ATCC 51659 >250 9.07 7.11 to 11.6 3.28
S. aureus ATCC BAA-1718 NT 2.31 1.69 to 3.16 0.835
S. aureus ATCC 33592 >250 0.883 0.526 to 1.48 0.319
P. aeruginosa PAO1 >250 1.17 0.866 to 1.62 0.429
P. aeruginosa ATCC BAA-2110 NT 0.130 0.100 to 0.168 0.0470
A. baumannii ATCC 9955 NT 0.233 0.129 to 0.419 0.0842
A. baumannii ATCC BAA-1794 >250 0.126 0.0899 to 0.176 0.126
A1P E. coli ATCC 4157 NT 9.2 5.90 to 14.4 2.24
E. coli ATCC 51659 >250 2.51 1.55 to 4.08 0.611
S. aureus ATCC BAA-1718 NT 36.5 25.1 to 53.1 8.89
S. aureus ATCC 33592 >250 2.68 1.51 to 4.76 0.653
P. aeruginosa PAO1 >250 38.6 4.01 to 372 9.4
P. aeruginosa ATCC BAA-2110 NT >800 >195
A. baumannii ATCC 9955 NT 24.0 1.52 to 7.19 5.84
A. baumannii ATCC BAA-1794 >250 2.36 0.370 to 1.75 0.575
LL-37 E. coli ATCC 4157 NT 0.191 0.109 to 0.337 0.0425
E. coli ATCC 51659 >250 0.298 0.208 to 0.428 0.0663
S. aureus ATCC BAA-1718 NT 0.839 0.497 to 1.42 0.187
S. aureus ATCC 33592 >250 0.208 0.138 to 0.312 0.0462
P. aeruginosa PAO1 >250 0.647 0.598 to 6.96 0.144
P. aeruginosa ATCC BAA-2110 NT 2.26 1.50 to 3.41 0.503
A. baumannii ATCC 9955 NT 1.46 1.04 to 2.07 0.825
A. baumannii ATCC BAA-1794 >250 0.804 0.370 to 1.75 0.179
Polymyxin B E. coli ATCC 4157 NT 2.50 0.831 to 7.50 1.92
E. coli ATCC 51659 NT 0.00181 0.00135 to 0.00244 0.00139
P. aeruginosa PAO1 NT 0.00568 0.00458 to 0.00704 0.00436
P. aeruginosa ATCC BAA-2110 NT 0.0109 0.00706 to 0.0157 0.00837
A. baumannii ATCC 9955 NT 0.121 0.0895 to 0.164 0.0013
A. baumannii ATCC BAA-1794 NT 0.0131 0.0111 to 0.0153 0.0101
Vancomycin S. aureus ATCC BAA-1718 1 >100 >69.0
S. aureus ATCC 33592 1 >100 >69.0
MIC is determined in Mueller Hinton Broth II. EC50 is determined in 10 mM sodium phosphate buffer. NT Not Tested
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activity (EC50 < 1 μg/ml) against drug sensitive and MDR
A. baumannii (ATCC BAA-1794), MRSA (ATCC
33592), and MDR P. aeruginosa (ATCC BAA-2110). It
was also found that Apo5 and Apo6 were somewhat less
active against both strains of E. coli tested, with EC50
values ranging from 4 to 20 μg/ml, though our previous
work demonstrated that these peptides were extremely
effective against E. coli ATCC 25922 [8]. Apo5 and Apo6
had differing activities against P. aeruginosa PAO1;
Apo5 was found to have stronger activity against this
strain than Apo6 (0.0878 μg/ml vs 1.17 μg/ml).
A1P was found to have stronger broad-spectrum
activity than anticipated from our previous study [8].
Although A1P had weak activity against P. aeruginosa
PAO1 (EC50 = 38.6 μg/ml), it was not effective at con-
centrations tested against MDR P. aeruginosa (ATCC
BAA-2110) (Table 4). A1P had stronger antimicrobial
activity against MDR strains of E. coli (ATCC 51659), S.
aureus (ATCC 33592), and A. baumannii (ATCC BAA-
1794), with EC50 values between 2 and 3 μg/ml, than
against the antibiotic sensitive strains tested, which had
EC50 values ranging from 9 to 36 μg/ml.
Membrane permeabilization and depolarization by
peptides
To determine whether Apo5, Apo6, and A1P interacted
with the bacterial membrane, each peptide’s ability to
disrupt or permeabilize the membrane was measured by
the ethidium bromide uptake assay, while membrane
depolarization was measured with the fluorescent chem-
ical DiSC3(5), which is sensitive to the polarization of
membranes.
When the ethidium bromide uptake assay was per-
formed (Fig. 5a), it was found that Apo5 and Apo6
permeabilized the E. coli membrane at concentrations at
50 μg/ml quickly, comparable to control peptide LL-37,
a known pore-forming peptide. Neither Apo peptide
permeabilized membranes at lower concentrations. Like
LL-37, these peptides permeabilized the membrane in a
significant manner (p < 0.001), with peak fluorescence
occurring within 3 min. A1P also permeabilized the
membrane at 50 μg/ml significantly higher than the un-
treated control (p < 0.001), but displayed very different
and slower kinetics. With this peptide, fluorescence
gradually increased over the 20 min experimental time
frame, until reaching nearly equivalent maximum fluor-
escence as Apo5 and Apo6 by the end of the experiment
(Fig. 5b).
Depolarization of a bacterial membrane indicates tran-
sient membrane disruption that allows for ion leakage,
which damages the proton motive force and other gradi-
ents that store chemical energy. As shown in Fig. 6,
within 1 min it was found that Apo5 and Apo6 depolar-
ized bacterial membranes at concentrations as low as
0.5 μg/ml (p < 0.001), with depolarization showing a
clear dose-dependent response to peptide concentration.
A1P did not depolarize membranes except at the highest
concentration tested, 50 μg/ml (p < 0.05). Depolarization
signals at this concentration were well below those
achieved at the lowest concentrations used for Apo5,
Apo6, and LL-37 (p < 0.001).
These results indicate that Apo5 and Apo6 depolarize
the bacterial membrane quickly, suggesting membrane
disruption is the mechanism by which these peptides kill
bacteria. A1P does not depolarize the membrane, nor
does it form pores quickly except at high concentrations.
This implies that the primary mechanism of A1P is not
related to membrane disruption.
DNA binding
Some peptides, such as LL-37 or histone-derived Buforin
II, bind nucleic acids [4, 41], inhibiting translation and
transcription or promoting mutagenesis. In general, this
Fig. 5 Pore-forming activity by Apo5, Apo6, and A1P. An increase in
fluorescence demonstrates greater binding of DNA by ethidium bromide,
which indicates the formation of pores in the bacterial membrane. a.
Kinetics of permeabilization and binding of ethidium bromide to DNA
after treatment with Apo5 (dashes), Apo6 (solid line), A1P (dots), and
LL-37 (dash dot) b. Permeabilization of membrane after 20 min
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binding mechanism has been shown to be non-specific
[41, 42]. To determine if any of the CAMPs were able to
bind DNA, a gel shift assay was performed, shown in
Fig. 7. A1P bound DNA only at very high ratios, needing
at least 20 times more mass of peptide than DNA to in-
hibit DNA movement. Apo6 did not bind DNA at any
concentration, while Apo5 bound DNA only at the high-
est concentration tested. It is unlikely that the primary
mechanism of action of these three peptides is related to
DNA binding.
Cytotoxicity
The physiochemical properties of CAMPs preclude sig-
nificant host-cell cytotoxicity; however, some CAMPs,
such as SMAP-29, have been found to cause damage to
eukaryotic cells at similar concentrations. Cytotoxicity
against red blood cells and A549 lung epithelial cells was
measured. For red blood cells, a spectrophotometric
assay that measures free heme was used, while an MTT
assay was used for A549 cells. As shown in Table 4,
these peptides have EC50’s between 0.07–39 μg/ml. In
Fig. 8a, hemolytic activity is shown as percent hemolysis.
All four peptides showed hemolysis of RBCs of less than
1 % at 300 μg/ml, a, comparable to the control peptide
LL-37. No statistically significant difference was found be-
tween the untreated control and all peptides, indicating
that Apo5, Apo6, and A1P are not hemolytic. The MTT
assay was used to measure cytotoxicity of other cells lines.
After 24 h exposure, concentrations of peptide up to
100 μg/ml were not significantly cytotoxic against A549
cells, as shown in Fig. 8b, while the EC50 against A. bau-
mannii was less than 1 μg/ml of Apo peptide.
Discussion
Using our CAMP discovery process and only 100 μl of
alligator plasma, we have previously identified five novel
antimicrobial peptides from A. mississippiensis that ex-
hibit antibacterial activity [8]. Our bioprospecting-based
process provides a unique access to the antimicrobial
peptidome, and is a significant advance in the effort to
identify novel antimicrobial peptides in nature. In this
study, we present detailed characterization of the struc-
ture and function of three alligator plasma-derived pep-
tides: Apo5, Apo6, and A1P. We demonstrated that
Apo5, Apo6, and A1P are potent antimicrobial peptides
that extend their efficacy against multi-drug resistant
and clinically relevant pathogens, such as A. baumannii.
The two peptides Apo5 and Apo6 are both derived
from a predicted apolipoprotein C-1 in A. mississippien-
sis. Apolipoproteins bind lipids; apolipoprotein C-1 in
particular is known to bind phospholipids and is a
marker of apoptosis [11, 12, 43, 44]. Apo6 is a smaller
derivative of Apo5; Apo5 contains residues 64-88 of pre-
dicted apolipoprotein C-1, while Apo6 contains residues
67-88. These peptides were very active against Gram-
negative bacteria. Previously, Apo5 and Apo6 were each
found to be strongly active against E. coli ATCC 25922
and P. aeruginosa ATCC 9027 while EC50 values were
much higher for virulent Staphylococcus aureus (ATCC
25923). We discovered that Apo5 and Apo6 are predom-
inantly helical peptides. Their mode of antibacterial
Fig. 6 Membrane depolarization activity by Apo5, Apo6, and A1P.
Depolarization determined using DiSC3(5) for each peptide at
50 μg/ml (■), 5 μg/ml ( ), 0.5 μg/ml ( ), as well as no
treatment ( )
Fig. 7 DNA binding by a Apo5, b Apo6, c A1P, and d LL-37 as measured using a gel shift assay. Ratio of DNA:CAMP is shown
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activity appears to be primarily through membrane
interaction. At low concentrations (approximately the
EC50 for all bacteria), Apo5 and Apo6 depolarized the
membrane of E. coli. At high concentrations, well above
the EC50 for all bacteria tested, these peptides more
strongly disrupted the bacterial membrane, possibly via
pore formation, allowing for the escape of large cellular
milieu. Based on these observations, it seems that the
primary mode of action of these apolipoprotein-derived
peptides is membrane perturbation and depolarization.
The antimicrobial activity of apolipoproteins has been
highlighted in other organisms, although typically apoli-
poprotein A is studied [9–12, 14, 45]. Many whole apoli-
poproteins have been found to have antimicrobial
activity against a variety of bacteria, as well as some
viruses. Apolipoprotein A-1 from various fishes have
been shown to have antimicrobial activity against E.
coli [11, 12, 46], Streptococcus spp. [11] and fish
pathogens such as Mycobacterium marinum [11] and Yer-
sinia ruckeri [12]. The antimicrobial activity of human
apolipoprotein A-1 has also been examined, and several
groups have found that this protein is effective against
E. coli, Klebsiella pneumoniae, and Yersinia enterocoli-
tica [10, 44]. The primary mode of action of apolipo-
protein A-1 seems to be as a detergent; it has been
shown to bind lipids including LPS and to dissolve
micelles [12, 44, 47]. The LPS-binding activity in
particular has been shown to be reliant on the N-
terminus of the protein [44]. The mechanism of
action and antimicrobial activity of apolipoprotein C-
1 has not yet been explored, but it likely binds lipids
as some part of its mechanism.
Apo5 and Apo6 were not found to bind E. coli LPS as
part of its mechanism (data not shown), but these two
peptides are located on the C-terminus of apolipoprotein
C-1. To our knowledge, fragments of apolipoproteins
have not been characterized prior to this work. Other
groups have studied synthetic mimetics of apolipopro-
tein E, which have been found to have anti-infective
effects against HIV-1 and HSV-1 [48] and antimicrobial
activity against MDR bacteria [14]. This characterization
of the broad antimicrobial activity of apolipoprotein C-
1-derived peptides in the present work adds to the
understanding of this family of CAMPs.
A1P is a fragment of a predicted alpha-1-proteinase.
A1P contains amino acids 394-428 of this proteinase
inhibitor. Though the primary role of alpha-1-proteinase
is the inhibition of human neutrophil elastase, it also in-
hibits a number of other proteases, such as proteinase 3
[49], some kallikreins [50], matriptase [51], and caspase-
3 [52]. It has also been shown to have an important role
in immune modulation. Alpha-1-proteinase is an acute-
phase reactant; levels of this protein increase 3 to 4 fold
in response to PAMPs or inflammation [53, 54]. Alpha-1-
proteinase is involved in neutrophil degranulation [55]. It
has also been shown to protect mice from LPS- and TNF-
associated lethality, possibly by preventing the release of
membrane-bound TNF [56]. Alpha-1-proteinase also in-
teracts with human neutrophil peptides to reduce their
cytotoxic affects towards lung cells; this has been demon-
strated in vitro and in vivo [57].
This protein may play a role in the disease progression
of some bacteria such as Francisella tularensis. Studies
have shown that alpha-1-proteinase is decreased during
a pulmonary F. tularensis challenge in mice. This could
lead to unchecked neutrophil elastase activity, which
damages the alveoli and lung tissue, allowing bacteria to
quickly disseminate through the body and to the liver
[58]. Though other protease inhibitors have been shown
to have antimicrobial activity, previously α-1-proteinase
and its fragments had only been shown to have anti-
infective activity, not direct antimicrobial activity. The
Fig. 8 Peptide Cytotoxicity a. Hemolysis of sheep red blood cells
was measured using a photometric assay after exposure to 300 μg/ml
for 1 h and b. Inhibition of Proliferation of A549 human lung epithelial
cells measured using the MTT assay after 24 h exposure. Apo5 (■),
Apo6 ( ), A1P ( ), LL-37 ( )
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whole protein has shown to have protective activity
against P. aeruginosa, by suppressing bacterial prolifera-
tion and tissue inflammation [59, 60]. Whole alpha-1-
proteinase, as well as a fragment and cyclic derivatives,
have demonstrated the ability to prevent HIV-1 infection,
possibly by inhibiting production of the virus [61–63].
Interestingly, this anti-HIV-1 fragment is the C-terminal
fragment of the protein, where A1P is also found. The
antibacterial mechanism of action is not yet clear from the
scope of this study. A1P was not found to depolarize the
bacterial membrane or form larger pores except at con-
centrations much higher than calculated EC50 values. A1P
was also not found to bind DNA effectively. However,
considering that A1P does interact with the membrane
and form pores in high concentrations slowly, as discussed
in section 3.4, it is possible that A1P crosses the bacterial
membrane and interacts with a non-nucleic acid target or
inhibits bacterial proteases that are necessary for viability.
It seems possible that the anti-HIV-1 function described
by other groups is the same function that kills bacteria.
Vancomycin and polymyxin B are drugs of last resort
in the treatment of extremely multi-drug-resistant bac-
teria, and yet resistance to even these two drugs is
currently rising [64–66]. In addition, both vancomycin
and polymyxin B are known to be hemolytic and cyto-
toxic to some cell lines [67, 68]. It is clear that new anti-
microbials are needed, particularly drugs with low
cytotoxicity. LL-37 is a well-studied peptide with broad-
spectrum activity. In this study, we have used LL-37 as a
peptide control. We found that the alligator CAMPs
tested had comparable activity to LL-37 against some
species. LL-37 was found to have very strong activity
against all species tested, with EC50 values all below
3 μg/ml. Apo5 and Apo6 had comparable activity against
strains of P. aeruginosa, A. baumannii, and MRSA
(ATCC 33592), but were less active against strains of E.
coli tested, with EC50 values ranging from 2–20 μg/ml.
These peptides also had similar membrane perturbation
activity as LL-37, with membrane depolarization at low
concentrations and pore formation and disruption at
very high concentrations. A1P had weaker activity than
LL-37 against susceptible strains of bacteria tested (EC50
values between 9 and 40 μg/ml) but stronger and com-
parable activity to LL-37 against drug-resistant strains of
E. coli, S. aureus, and A. baumannii, with EC50 values
less than3 μg/ml. Interestingly, A1P was not active
against drug-resistant P. aeruginosa. We performed ex-
periments with ethidium bromide and Disc3(5) using
A1P against both strains of P. aeruginosa at 40 μg/ml,
the approximate EC50 of A1P against P. aeruginosa PAO1,
to determine if this difference in activity was due to differ-
ences in membrane interaction (data not shown). How-
ever, there was no difference in either depolarization or
disruption. In our previous work, we found that A1P was
least effective against P. aeruginosa ATCC 9027 in a panel
also including other strains of S. aureus, E. coli, and Bacil-
lus cereus [8]. It is possible that P. aeruginosa is intrinsic-
ally resistant to this particular peptide.
The novel CAMPs characterized here are among the
first discovered using our hydrogel bioprospecting tech-
nology, illustrating the power of this technology to cap-
ture naturally occurring small peptides with net cationic
charge and antimicrobial activity [8]. Considering the
strong and broad-spectrum activity of these CAMPs, it
seems likely that there is a greater role for protein frag-
ments in peptide-based innate immunity than previously
thought. Apolipoproteins are a highly conserved class of
proteins, and it is very likely that fragments are produced
in similar patterns across species. For example, though the
human apolipoprotein C-I (accession AAH55093) shares
41 % identity with the American alligator version, the C-
terminal 25 aa on each protein, where Apo5 is found,
shares 59 % identity. This theoretical fragment of the
human apolipoprotein C-I, with the sequence ELSAKMR
EWFSETFQKVKEKLKIDS, is also predicted to be helical,
with a weaker hydrophobic moment (0.375 μH) and simi-
lar hydrophobicity (36 %), but is less charged the alligator
Apo5 (+1), according to Heliquest [26] and The Anti-
microbial Peptide Database [16]. The human peptide is
not predicted to be antimicrobial by CAMPR3, but neither
is Apo5, and we have discussed previously the weaknesses
of commonly used antimicrobial peptide predictors [8].
We are currently working to determine whether some of
these fragmentation patterns are conserved across species.
In addition, these CAMPs are more effective against
drug-resistant strains than normal laboratory strains, in-
dicating these CAMPs may be valuable basis for treat-
ments against multi-drug resistant bacteria. Considering
the strength of Apo5 and Apo6 on MDR A. baumannii
in particular and the low cytotoxicity of these peptides,
these are strong candidates for in vivo testing, or to use
as scaffolds for stronger synthetic CAMPs.
Conclusion
Apo5, Apo6 and A1P are antimicrobial peptides found
the plasma of the American alligator. Apo5 and Apo6
are alpha-helical C-terminal fragments of apolipoprotein
C-1. These peptides have strong activity against S. aur-
eus and a number of Gram-negative bacteria, including
MDR A. baumannii and P. aeruginosa. Apo5 and Apo6
primarily work by depolarizing the bacterial membrane.
A1P is a C-terminal fragment of the alligator alpha-1-
proteinase. It has strong activity against S. aureus and a
number of Gram-negative bacteria, but not MDR P. aer-
uginosa. A1P has a mixed structure, and the mechanism
of action was not clear based on experiments performed;
however, it does seem to slowly disrupt the bacterial
membrane.
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These peptides are fragments of conserved proteins
found in many animals, indicating that these peptides
could play a role in immune response of many animals.
In addition, new antimicrobials are desperately needed
against MDR Gram-negative bacteria. Apo5 and Apo6 in
particular have strong activity against MDR pathogens of
clinical interest, and the native peptides or synthetic var-
iations will make strong candidates for in vivo testing
and pre-clinical trials.
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